1Stanberry LR, Jorensen DM.Nahmiae AJ. Herpes simplex viruses 1 and 2. In:Erans AS,Kaslow RA, ed.Viral infectons of humans:epidemiology and control.4th ed .New York:Plenum Medical Book Company, 1997, 419-454.
3Lagging LM, Meyer K, Hoft D, et al.Immune responses to plasmid DNA encoding the hepatitis C virus oore protein. J Virol, 1995, 69: 5859-- 5863.
4Roger JW. DNA sequence of the Herpes simplex virus type 2 glyooprotrin D geng .Gesne, 1983,26:307--312.
5Boume N, Milligan GN, Schleiss MR, et al. DNA immunization connfers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine, 1996,14:1230.
6Mascola JR. Herpes simplex virus vaccines -why don' t antibodies protect ? JMMA 1999, 282(4) : 379- 380.
9Freeman EE, White RG, Bakker R, et al. Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub- Saharan Africa[J]. Vaccine, 2009,27(6) :940-946.
10Paz-Bailey G, Ramaswamy M, Hawkes SJ, et al. Herpes simplex virus type 2 : epidemiology and management options in developing countries[J]. Postgrad Med J, 2008,84(992) :299-306.
